Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Mar 22, 2023

BUY
$3.91 - $7.15 $9,775 - $17,875
2,500 New
2,500 $10.6 Million
Q1 2020

Mar 24, 2023

BUY
$2.25 - $5.64 $5,625 - $14,100
2,500 New
2,500 $7 Million

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $118M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.